Here, we describe a new HLA-B*3501-restricted cytotoxic T lymphocyte (CTL) epitope in the influenza A virus (H3N2) nucleoprotein, which was found to exhibit a high degree of variation at nonanchor residues. The influenza virus variants emerged in chronological order, and CTLs directed against old variants failed to recognize more recent strains of influenza A virus, indicating an escape from CTL immunity.
CD8
ϩ cytotoxic T lymphocytes (CTLs) contribute to the control of viral infections by recognizing antigenic peptides of viral proteins presented by major histocompatibility complex (MHC) class I molecules on infected cells. The specific recognition of these MHC-peptide complexes by CTLs may lead to the elimination of virus-infected cells. One of the mechanisms exploited by viruses to evade recognition by CTLs (19, 23, 28) involves antigenic variation in CTL epitopes or mutations in sequences flanking these epitopes. Antigenic variation in CTL epitopes, resulting in the evasion of immune surveillance by specific CTLs, has been described for several viruses that cause chronic infections, including Epstein-Barr virus (5, 8, 9, 12) , human immunodeficiency virus (4, 7, 13, 14, 22, 26) , hepatitis B virus (1, 2) , and hepatitis C virus (6, 35) .
Recently, mutations were also found at the anchor residue of an HLA-B*2705-restricted epitope of the influenza A virus nucleoprotein (NP), which consisted of amino acids 383 to 391 (NP [383] [384] [385] [386] [387] [388] [389] [390] [391] ). Both the R 384 G and the R 384 K mutations abolished class I-restricted presentation and allowed for escape from CTL recognition (34) . Thus, these viruses, which cause acute infections in a significant portion of the human population annually, can escape from immune surveillance by CTLs in addition to escaping from neutralizing antibodies (antigenic drift and antigenic shift).
For the identification of new CTL epitopes, CD3 ϩ -and CD8
ϩ -T-cell clones were generated by limiting dilution (34) from the peripheral blood mononuclear cells (PBMC) of an HLA-A*0101-, HLA-A*0201-, HLA-B*0801-, and HLA-B*3501-positive donor after in vitro stimulation with influenza virus Resvir-9, a reassortant vaccine strain of A/Nanchang/ 933/95 (3). For the initial specificity testing of the T-cell clones, an enzyme-linked immunospot assay was used, as described previously (3), with cells from the infected autologous B-lymphoblastoid cell line (BLCL) as stimulator cells. Clone 1980-1 was found to recognize a yet unidentified epitope in an HLA-B*3501-and HLA-B*3503-restricted fashion, as demonstrated with cells from the HLA-matching and -nonmatching infected BLCL as target cells ( Fig. 1A ; also data not shown). This clone was specific for the NP of influenza A virus (H3N2), since it lysed target cells incubated with recombinant NP (rNP) (Fig.  1B) , as described previously (3, 33) . By using a CTL epitope prediction program (25) (http://www.umds.ac.uk/tissue), putative HLA-B*3501-restricted epitopes in the NP of influenza A virus (H3N2) were predicted. The 9-mer with the highest ranking, LPFEKSTVM (NP 418-426 /1980), was synthesized and was found to be recognized by the T-cell clone 1980-1 in a CTL assay (Fig. 1C) . Removal of the C-terminal methionine abolished recognition by clone 1980-1 (Fig. 1D) . A similar result was observed when the lysine at the N terminus of the 9-mer epitope LPFEKSTVM was removed. Addition of one amino acid at the N or C terminus of the epitope did not significantly improve recognition of target cells, indicating that NP [418] [419] [420] [421] [422] [423] [424] [425] [426] was the minimal epitope.
Experiments with rNPs from different virus strains indicated that clone 1980-1 did not react with the rNP obtained from A/Hong Kong/2/68 (H3N2) (data not shown). Therefore, known NP 418-426 sequences of influenza A viruses obtained from the influenza sequence database (http://www.flu.lanl.gov) were compared. It was found that the amino acid sequence in the epitope varied at four positions and that these variants emerged in chronological order. All variants and their designations are shown in Table 1 . Although the strains used for NP sequence comparison were not controlled for passage history of the strains (eggs grown or passaged in mammalian cell lines), it is unlikely that this has biased the analysis, since no immediate selective pressure on the NP was observed by adaptation in eggs, as was the case for the hemagglutinin (29) .
A T2 cell line expressing HLA-B*3501 (30) was used to assess the affinity of the NP 418-426 epitopes for the HLA-B*3501 molecule as previously described (32 (Table 2) , which suggests that the three peptides represent CTL epitopes. For comparison, the IC 50 of a previously described HLA-B35-restricted influenza A virus epitope, M1 128-135 , was determined and found to be higher than the highest concentration used (20 M) .
The frequency of peptide-specific CTL precursors was determined for the NP 418-426 /1980, NP 418-426 /1972, and NP 418-426 /1957 variants of the epitope and found to differ considerably among four HLA-B35 ϩ donors (Table 3 Fig. 2C ; also data not shown). With the other two CTL clones (1980-2 and 1980-3), some cross-reactivity was observed with the epitopes in older influenza A virus strains ( Fig. 2B ; also data not shown). The absence of recognition of the NP 418-426 /1980 epitope by CTLs directed against older variants was also demonstrated with PBMC obtained from two donors stimulated in vitro with influenza virus A/Victoria/3/75 ( Fig. 3E ; also data not shown). These PBMC did, however, recognize the homologous NP 418-426 /1972 epitope. PBMC of some donors displayed cross-reactivity with both variants after stimulation with A/Victoria/3/75 or Resvir-9 (Fig. 3) . This cross-reactivity can be explained by the expansion of cross-reactive CTLs in PBMC, a phenomenon previously described in C57BL/10 mice infected with different strains of influenza A virus (15) . Finally, one donor (donor 5017) did not respond at all after stimulation with A/Victoria/3/75 (Fig. 3C) .
To exclude the influence of consecutive natural infections with various influenza A viruses on the NP 418-426 -specific CTL response, we obtained HLA-A2
ϩ HLA-B35 ϩ PBMC cryopreserved between the years 1982 and 1984. Since this occurred shortly after the introduction of the NP 418-426 /1980 variant epitope, the chance of an infection with an NP 418-426 /1980 variant virus in these donors was relatively small. The NP 418-426 /1980 epitope was not recognized by the PBMC of these donors (donors 1 and 2) (Fig. 4) after stimulation with both a recent strain of influenza virus (Resvir-9) and A/Victoria/3/75, which contained the NP 418-426 /1972 epitope. The lack of NP 418-426 /1980-specific activity was not caused by the absence of virus-specific CTL activity, since the NP 418-426 /1972 variant epitope and the conserved HLA-A*0201-restricted M1 58-66 epitope were recognized.
Based on these findings, we argue that in addition to the variation in the HLA-B8-and HLA-B*2705-restricted epitopes, NP 380-388 and NP 383-391 , respectively, the variation in this newly identified HLA-B*3501-restricted NP 418-426 epitope is driven by CTL immunity, leading to escape from recognition by these CTLs. The variations in the NP 380-388 and NP 383-391 epitopes were found at the anchor residues (R 384 G mutation) of the respective 9-mers (34). In the NP 418-426 epitope, the anchor residues for binding to HLA-B35 were perfectly conserved in all virus strains isolated and sequenced since 1933. It can be speculated that variation at these residues is restricted by functional constraints. For example, an R 267 A mutation within an HLA-A3-restricted epitope has been shown to affect RNA binding by NP (11 is unlikely that the mutations in the NP 418-426 epitope were selected based on the improved fitness of these viruses. HLA-B35-positive individuals constitute a significant portion of the human population, ranging from 5% in Orientals to 10% in Caucasians (21) . tive individuals because the mutations in the NP 418-426 epitope did not reduce the fitness of these viruses. It is of interest that the infection of mice transgenic for a single T-cell receptor (TCR) specific for the H-2D b -restricted NP 366-374 epitope of influenza A virus resulted in the emergence of viruses containing amino acid mutations in this epitope, which impaired the presentation of viral peptides by MHC class I molecules or interfered with T-cell receptor recognition (27) . Other mutations at nonanchor residues have been described only for sporadic virus isolates, and their effect on T-cell recognition was not studied (24) . A mutation in a CTL epitope (NS1 122-130 ) in the (not naturally occurring) high-yield vaccine strain of influenza virus A/Texas/36/91 (31) inhibited recognition by a CTL clone. Other mechanisms based on mutations in CTL epitopes contributing to reduction or elimination of CTL recognition have been described, like "original antigenic sin" (18) , antagonism (16, 17) , and anergy. Although original antigenic sin and anergy were not investigated in great detail, in one of the PBMC samples, obtained in 1982, a response was found that was specific for the NP 418-426 /1972 epitope but not for the homologous NP 418-426 /1980 epitope used for stimulation.
In conclusion, a new variable CTL epitope was identified in the NPs of influenza A viruses. Epidemiological and immunological evidence indicates that the variation found in this epitope was the result of antigenic drift resulting from immune pressure mediated by specific CTLs. Thus, in addition to the introduction of mutations in the surface glycoproteins, which allows for escape from antibody-mediated immunity, further evidence which shows that influenza viruses can escape from CTL-mediated immunity is accumulating. This would make these viruses masters in disguise, partially explaining their relative success in infecting a large portion of the human population every year for the past several decades. 
